Judy Chuk

Judy Chuk joined Flagship Pioneering in 2024 as an Operating Partner helping drive exploration, value creation, strategy, and execution for ProtoCos and NewCos.

Judy’s career has spanned many disease areas in both large pharma and biotech settings. Most recently, she was Senior Vice President of Strategy, Portfolio, and Governance at Bicycle Therapeutics, where she drove long-term planning and growth of the company from a research group to a billion-dollar clinical-stage company. Prior to Bicycle, Judy was Vice President of Strategy and Operations at Enzyvant Therapeutics (acquired by Sumitovant Biopharma in 2019), where she scaled the company from virtual operations to an end-to-end company with research, development, and commercial capabilities. Judy has also worked extensively in R&D Operations in Pfizer's Rare Disease Research Unit and began her career at L.E.K. Consulting's life sciences practice, advising biopharma clients on business strategy issues.

Judy has a Ph.D. from Harvard University, where she studied molecular mechanisms of cellular differentiation, and a B.A. in Chemistry from Rutgers University.